Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion. (October 2022) - Moriarty, A.; Flores, J.; Stackpole, A.; Ulmer, S.; Papadopoulos, K.; Patnaik, A.; Rasco, D.; Calvo, E.; Moreno, V.; Wick, M.